Premium
Serotonin toxicity from co‐administration of escitalopram and mirtazapine
Author(s) -
Lam Y. W. Francis
Publication year - 2015
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30051
Subject(s) - mirtazapine , serotonergic , serotonin syndrome , serotonin , escitalopram , pharmacology , tricyclic , monoamine oxidase , medicine , antidepressant , serotonin reuptake inhibitor , serotonin uptake inhibitors , reuptake inhibitor , chemistry , fluoxetine , receptor , biochemistry , hippocampus , enzyme
Serotonin syndrome is a serious condition that can, rarely, result in fatality. It is usually caused by increased serotonin stimulation. The most common pharmacologic intervention that results in serotonin syndrome is the concurrent use of drugs that enhance central serotonergic activity, including monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin‐norepinephrine reuptake inhibitors (SNRIs). Other drugs also can increase central serotonergic activity.